Equities

Scilex Holding Co

SCLX:NAQ

Scilex Holding Co

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.03
  • Today's Change0.02 / 1.98%
  • Shares traded2.00m
  • 1 Year change-44.92%
  • Beta1.2008
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Scilex Holding Co's net income fell 389.35% from a loss of 23.36m to a larger loss of 114.33m despite revenues that grew 22.90% from 38.03m to 46.74m. An increase in the selling, general and administrative costs as a percentage of sales from 170.62% to 255.95% was a component in the falling net income despite rising revenues.
Gross margin68.24%
Net profit margin-233.88%
Operating margin-181.47%
Return on assets-102.93%
Return on equity--
Return on investment--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.